title: Late administration of a specific COX-2 inhibitor does not treat and/or prevent progression of gastric tumors in rats submitted to duodenogastric reflux procedure.
abstract: OBJECTIVE
  To assess whether late introduction of a specific COX-2 inhibitor (Meloxicam) can treat and/or prevent the progression of tumors in the stomach of rats submitted to duodenogastric reflux.
  
  
  METHODS
  Seventy five male Wistar rats, weighing 150 grams, were submitted to the induction of duodenogastric reflux through the pylorus. At 36 weeks of follow-up were established three experimental groups: DGR36 sacrificed immediately, DGR54 and DGR54MLX both sacrificed at 54th week of follow-up . The animals of the latter group were fed with a rat chow premixed with Meloxicam (2.0 mg/ kg feed; 0.3 mg / kg bw / day) and the other two with standard rat chow. The lesions found in the pyloric mucosa and gastrojejunal anastomosis were analyzed macroscopically and histologically. For statistical analysis was adjusted a generalized linear model assuming a binomial distribution with LOGIT link function.
  
  
  RESULTS
  No significant differences were found when comparing the incidences of benign tumor lesions (Adenomatous Hyperplasia), p=0.4915, or malignant (Mucinous Adenocarcinoma), p=0.2731, among groups.
  
  
  CONCLUSIONS
  Late introduction of specific COX-2 inhibitor (Meloxicam) did not treat and was not able to prevent the progression of tumoral lesions induced by duodenogastric reflux in the rat stomachs.
authors.affiliation: Departament of Surgery and Orthopedics, Faculty of Medicine, UNESP, Botucatu-SP, Brazil. paulor@fmb.unesp.br
authors.forename: Paulo Antônio
authors.initials: PA
authors.lastname: Rodrigues
authors.forename: Luiz Eduardo
authors.initials: LE
authors.lastname: Naresse
authors.forename: Maria Aparecida Marchesan
authors.initials: MA
authors.lastname: Rodrigues
authors.forename: Shoiti
authors.initials: S
authors.lastname: Kobayasi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage*; D018450:Disease Progression; D004383:Duodenogastric Reflux / Q000150:complications* / Q000601:surgery; D008297:Male; D008488:Medical Illustration; D000077239:Meloxicam; D011708:Pylorus / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D013843:Thiazines / Q000008:administration & dosage*; D013844:Thiazoles / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam